Clinical study on the treatment effect of EGCG on newly diagnosed open pulmonary tuberculosis

Objective To study the treatment effect of epigallocatechin gallate(EGCG) on newly diagnosed open pulmonary tuberculosis, and further optimize the treatment program. Methods A total of 205 open pulmonary tuberculosis patients were randomly divided into experimental group(102 cases) and control group(103 cases). The experimental group was treated with EGCG, and the control group was treated with placebo. The double-blind method was used during the treatment to compare the treatment effects of the two groups. Results Of 205 patients, there were 197 cases completed the treatment, 3 cases lost contact, 3 cases stopped treatment due to other reasons, 1 case died of accident and 1 case died of cerebral hemorrhage. Among them, 178 cases were clinically cured, 19 cases did not turn negative or failed to meet the standard in imaging, and need further treatment. The experimental group had obviously shorter mean negative conversion time as(1.72± 0.42) months than(2.13±0.51) months in the control group, and the difference was statistically significant(P<0.05). The experimental group had gained weight during treatment as(4.49±1.07) kg, which was(3.10± 1.66) kg in the control group, and the difference was statistically significant(P>0.05). The experimental group had fever time as(4.10±2.31) weeks, which was(5.33±1.74) weeks in the control group, and their difference was statistically significant(P<0.05). Conclusion EGCG treatment for newly treated open pulmonary tuberculosis patients can significantly shorten the sputum smear negative time, improve the patient’s condition, optimize the effect of chemotherapy. It is worthy of clinical promotion.